Most Recent
Telecom giant Optus has come up short in a Federal Court challenge to trademark registration for health services company Optum, with a judge saying the two company's marks -- despite the difference of just one letter -- were distinct enough.
A full bench of the Federal Court has dismissed an appeal by drug giant GlaxoSmithKline in a patent infringement case it brought over planned generic versions of its sustained-release Panadol.
Johnson & Johnson has struck back at an amended statement of claim filed in a class action over allegedly defective pelvic mesh, saying that lead applicants' claims do not meet the bar to proceed as a class action.
The Therapeutic Goods Administration is seeking feedback on its proposed process for handling advertising complaints when stricter new advertising rules for therapeutic products take effect later this year.
A judge on Tuesday consolidated two shareholder class actions against life sciences company Sirtex Medical and appointed Maurice Blackburn as lead lawyers for the joint proceedings.
German drug company Merck KGaA has filed a massive trade mark lawsuit against US pharmaceutical giant Merck Sharpe & Dohme in Australian federal court, claiming its use of the trade marked term "Merck" throughout its websites and apps accessible in Australia violates its trade mark and a 1970 agreement between the two.
The Office of the Australian Information Commissioner has confirmed a news report that it received a notice of a health data breach every other day after its mandatory data breach scheme took effect.
A lawyer for the University of Sydney has attacked ObjectiVision for failing to produce any commercial benefits from the glaucoma detection method at the centre of a patent infringement dispute, despite holding exclusive rights to the technology for 11 years.
Expert witnesses were pitted against each other Wednesday at a trial alleging generic makers infringed a patent covering the anti-depressant Lexapro, and Apotex' consultant took the brunt of it.
The maker of the anti-depressant Lexapro faced off Monday against Apotex, Aspen Pharma and Sandoz at a court hearing over the rights to make generic versions of the top-selling product, with a barrister for Lundbeck slamming the three companies' defence that their drugs were different.